Arcus Biosciences, Inc.
3928 Point Eden Way, Hayward, CA 94545
1800 Sierra Point Parkway, Brisbane, CA 94005
United States
228 articles about Arcus Biosciences, Inc.
-
Bob Goeltz to Join Arcus Biosciences as Chief Financial Officer
7/7/2020
Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that Bob Goeltz will join Arcus as Chief Financial Officer on August 1, 2020
-
Arcus Biosciences Announces New Employment Inducement Grants - June 09, 2020
6/9/2020
Arcus Biosciences, Inc., an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, announced that the Compensation Committee of the Company’s Board of Directors granted six new employees options to purchase a total of 138,000 shares of the Company’s common stock at an exercise price per share of $28.96, which was the closing price on June 8, 2020.
-
Check out this article for the impacts that Biotech Bay companies are experiencing due to COVID-19.
-
Arcus Biosciences to Participate in the Goldman Sachs 41st Annual Global Healthcare Conference Webcast
6/3/2020
Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that management will present at the Goldman Sachs 41st Annual Global Healthcare Conference Webcast on Wednesday, June 10, 2020 at 3:50 p.m. Eastern Time.
-
Arcus Biosciences, Inc. Announces Pricing of $302.5 Million Underwritten Public Offering of Common Stock
5/28/2020
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer therapies, today announced the pricing of an underwritten public offering of 11,000,000 shares of its common stock at a price to the public of $27.50 per share
-
Arcus Biosciences, Inc. Announces Commencement of Underwritten Public Offering of Common Stock
5/27/2020
Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer therapies, today announced that it has commenced an underwritten public offering of its common stock.
-
Gilead Sciences and Arcus Biosciences Establish 10-year Partnership to Co-develop and Co-commercialize Next-generation Cancer Immunotherapies
5/27/2020
Arcus to Continue to Independently Conduct Research on New Targets; Gilead to Receive Rights to Opt-In to All Programs in Arcus’s Pipeline for Length of Collaboration
-
Gilead Sciences and Arcus Biosciences signed a 10-year partnership deal to co-develop and co-commercialize a number of Arcus’s pipeline products.
-
Arcus Biosciences Appoints David Lacey, M.D., to Its Board of Directors
5/26/2020
Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that David Lacey, M.D. has joined the Company’s Board of Directors
-
Arcus Biosciences Announces New Employment Inducement Grants - May 11, 2020
5/11/2020
Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted three new employees options to purchase a total of 56,000 shares of the Company’s common stock at an exercise price per share of $30.08, which was the closing price on May 8, 2020.
-
Arcus Biosciences Announces First Quarter 2020 Financial Results and Corporate Updates
5/5/2020
AB680, the first small-molecule CD73 inhibitor in the clinic, continues in a Phase 1 dose-escalation combination trial for first-line treatment of pancreatic cancer, with a recommended dose for expansion anticipated to be established in mid-2020
-
Arcus Biosciences Announces New Employment Inducement Grants - April 9, 2020
4/9/2020
Arcus Biosciences, Inc. announced that the Compensation Committee of the Company’s Board of Directors granted thirteen new employees options to purchase a total of 381,200 shares of the Company’s common stock at an exercise price per share of $15.32, which was the closing price on April 8, 2020.
-
Arcus Biosciences Announces New Employment Inducement Grants
3/11/2020
Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensation Committee of the Company’s Board of Directors granted seven new employees options to purchase a total of 92,200 shares of the Company’s common stock at an exercise price per share of $18.00, which was the closing price on March 9, 2020
-
Arcus Biosciences Announces Fourth Quarter and Full Year 2019 Financial Results and Corporate Updates
3/5/2020
Advanced three molecules into randomized Phase 2 trials to evaluate Arcus’s potential best-in-class therapies and highly differentiated therapeutic combinations
-
Arcus Biosciences and Taiho Pharmaceutical Co., Ltd. Jointly Announce Taiho’s Exercise of Its Option for an Exclusive License to Zimberelimab (AB122) for Its Territories in Japan and Other Asian Countries
2/26/2020
Feb. 26, 2020 13:00 UTC Taiho’s in-licensing facilitates global development and commercialization of zimberelimab as a monotherapy and as a combination backbone for Arcus’s and Taiho’s oncology portfolios Zimberelimab exhibits clinical activity and a safety profile consistent with those of currently approved anti-PD-1 therapies Broad development program delivering randomized data in 2020 for zimberelimab in multiple novel combinations, including with AB154, Arcus’s a
-
Arcus Biosciences to Present at the 9th Annual SVB Leerink Global Healthcare Conference
2/12/2020
Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that management will present at the 9th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 26, 2020 at 9:30 a.m. Eastern Time in New York, NY.
-
Arcus Biosciences and Genentech, a Roche company, are partnering on two clinical trials for colorectal and pancreatic cancer. They will evaluate Arcus’s AB928 in various combinations.
-
Arcus Biosciences, in Collaboration with Genentech, Announces Two Randomized Clinical Studies to Advance AB928, a Dual Adenosine Receptor Antagonist, into Novel Combinations for Colorectal and Pancreatic Cancers
12/18/2019
Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company discovering and developing highly-differentiated therapies, today announced a clinical collaboration with Genentech, a member of the Roche group, for the evaluation of novel combinations with AB928, Arcus’s dual antagonist of adenosine receptors A2aR and A2bR, for colorectal (CRC) and pancreatic (PDAC) cancers.
-
BioSpace Movers & Shakers, Dec. 13
12/13/2019
Pharma and biotech companies strengthen their leadership teams and boards with this week's hires. -
Arcus Biosciences Appoints Patrick Machado, J.D., to its Board of Directors
12/12/2019
Mr. Machado will also serve as a member of the company’s Nominating and Corporate Governance Committee.